Evaluating AD1208 for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and tolerability of the drug AD1208 in patients with progressive, locally advanced, or metastatic solid tumors. Participants will receive AD1208 daily for a minimum of one treatment cycle, with regular check-ups and monitoring for adverse effects. The study includes a dose-escalation approach to determine the maximum tolerated dose and the recommended phase 2 dose for both monotherapy and combination therapy. The trial will involve detailed tracking of participants' health and any side effects experienced during the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female subjects ≥19 years of age
* Willing to consent to participate in study and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
* Histologically and/or cytologically confirmed any progressive, locally advanced (unresectable), or metastatic solid tumors that have relapsed or are refractory following the last line of treatment and for which prior standard therapy has been ineffective, standard therapy does not exist or is not considered appropriate.
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Life expectancy of at least 12 weeks
* Subjects with adequate hematologic, hepatic, and renal functions confirmed based on the screening laboratory test within 2 weeks prior to the first administration of IP.
* Female subject who is surgically sterile, is postmenopausal, or agrees to use a highly effective method of birth control (2 methods strongly recommended) during the study and for 6 months following the last dose of IP.
* Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or for the time the partner is breastfeeding throughout the study period and for 6 months after the final administration of IP.

Exclusion Criteria:

* Untreated active brain metastases.
* has leptomeningeal disease.
* unrecovered \> Grade 1 from the adverse event of prior therapy except for alopecia.
* has an active autoimmune disease requiring systemic treatment within the past 2 years.
* Active interstitial lung disease (ILD) or pneumonitis or a history of ILD.
* Subject has received the following treatment;

  * prior anticancer monoclonal antibody treatment or investigational therapy
  * prior any chemotherapy
  * prior radiotherapy
  * Major surgery
* Clinically significant (i.e., active) cardiovascular disease
* known positive of human immunodeficiency virus (HIV) infection.
* Active hepatitis B or C subjects.
* known allergic reaction for active ingredients or inactive ingredients such as excipients of Investigational product.
* Live vaccine administered against infectious disease.
* Gastrointestinal (GI) track disease causing the inability to take oral medication, malabsorption syndrome or uncontrolled inflammatory GI disease.
* having psychiatric illness/social situations that would limit compliance with study requirements.
* women with a positive pregnancy test at screening test.
* women who are breast feeding.
* subject has any condition because of which, in the opinion of the investigator, the participation would not be in the best interest of the subject.

Where it's running

• Seoul National University Bundang Hospital
  Seongnam-si, Gyeonggi-do, South Korea Recruiting
• Severance Hospital
  Seoul, South Korea Recruiting
• Samsung Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Soongyu Choi
• Email: cdm@avelostx.com
• Phone: 82 2-6949-4355

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing LXP1788 Injection for Advanced Solid Tumors

  This study is testing a new injection called LXP1788 to see if it can safely help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting at 2 sites Phase 1 LaunXP Biomedical Co., Ltd. · Taichung and 1 other locations · NCT06883539

• Adapting a communication program for Latinx cancer patients

  This study is testing a new communication program to help Spanish-speaking cancer patients in the Bronx talk about their health values with their nurses.

  Recruiting at 5 sites Memorial Sloan Kettering Cancer Center · New York, New York and 4 other locations · NCT04942717

• INV-1120 alone and with pembrolizumab for adults with advanced solid tumors

  This Phase 1 study will test whether the experimental drug INV-1120, given alone or with pembrolizumab, is safe and tolerable in adults with advanced solid tumors who have progressed after standard therapies.

  Recruiting Phase 1 Shenzhen Ionova Life Sciences Co., Ltd. · Lafayette, Indiana and 2 other locations · NCT04443088

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• DESCANSO/REST mental health program for Spanish-speaking Latino adults with cancer experiencing depression, insomnia, and fatigue

  This program will test whether a telehealth-delivered DESCANSO/REST intervention can help Spanish-speaking Latino adults with stage I–III solid tumors who are receiving systemic cancer treatment feel less depressed, sleep better, and have less fatigue.

  Recruiting at 8 sites Ponce Medical School Foundation, Inc. · Basking Ridge, New Jersey and 7 other locations · NCT07225088

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.